EpilepsyEarly Phase 1NCT07228338
Cholinergic Enhancement of Theta
A Early Phase 1 study testing COBENFY KarXT (50/20 mg) in people with Epilepsy and Seizures, run by University of Texas Southwestern Medical Center at 1 site in United States.
Trial summary
The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Epilepsy, Seizures, Cognitive Impairment, Mild
- What is being tested?
- COBENFY KarXT (50/20 mg)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2026to Dec 2031
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 - 75 years, all races/ethnicities, and both genders are eligible.
- Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.
- Able to read, understand, and provide written, dated informed consent prior to screening.
- In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.
Who cannot join
- Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.
- Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.
- Hepatic impairment (moderate or severe).
- Renal impairment (moderate or severe).
- Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.
- History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).
Show all 13Show fewer
- Untreated narrow-angle glaucoma.
- Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).
- Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.
- Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.
- Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.
- Drugs Eliminated by Active Tubular Secretion.
- Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Bradley C Lega, MD, 713-834-2497, Bradley.Lega@UTSouthwesthern.edu
About this study
Official title: Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity
The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.
The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.
Read more
Participants will complete two treatment arms. One of these will be with the drug, and the other will be control session. Participants will not be blinded to the study condition. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.
Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.
Read the detailed description
Patient Identification: The study team plans to recruit adult patients who are undergoing invasive electroencephalographic (EEG) monitoring as part of standard clinical procedure for the treatment of pharmacologically resistant epilepsy at UT Southwestern. Patients are identified from the pool of patients presented at the epilepsy management conference and approached when they present to the clinic for evaluation for seizure surgery. Patients are screened by a coordinator as well as anesthesiologist on the study team for contraindications which make them ineligible for receiving the drug.
Study procedures: Participation takes place only during the time that the electrodes are surgically in place. Active participation will end when the electrodes are removed. Tasks described below will be administered by key personnel on the study. The data will be de-identified and converted to signal data for processing and analysis. Study personnel, excluding the PI (aka 'experimenters') will perform analysis.
Once patients are in the epilepsy monitoring unit (EMU), subjects will be randomized to receive either a dose of 50 mg/20 mg orally BID of xanomeline and trospium chloride (COBENFY) for their initial session, or complete a control session. Approximately 2 hours after administration in the drug condition, the participant will complete an episodic memory task session. At least 24 hours following the first session (at least four half-lives after the first session), the participant will either receive the agent, or complete the control, depending on the first session. For example, if the patient received COBENFY the first day, they would complete the control the second day, and vice versa. Again, in the drug condition, the episodic memory task would occur 2 hours after administration.
Day 1: Randomized to receive either COBENFY or complete a control session (no drug); Complete episodic memory task session Day 2: Alternative session (control or CONBENFY) from day 1; Completes episodic memory task session
Neither participants nor researchers are blind to administration of Cobenfy KarXT, but this should not greatly impact the science of the study. Although there may be some performance effects, participants are being told that the drug may effect a particular brain activity, which may be difficult to model. The randomization will be generated by the pharmacy using a psuedorandomizer.
The participant's attending nurse will administer Cobenfy KarXT for the drug sessions 2 hours prior to the test.
Physiologic Monitoring: Patients in the epilepsy monitoring undergo EKG and pulse oxygen monitoring in addition to seizure monitoring electrodes at all times as part of routine care and this will not be interrupted during the study period. There is a certified epilepsy monitoring team available should the cholinergic effects enhance seizures. A board-certified anesthesiologist with specialist practice in neuroanesthesia will be immediately available within the hospital to respond with any other concerns. In our previous experiments using cholinergic modulation (antagonism), there have not been any adverse events. Specifically, there has not been an impact on seizure activity. While we do not anticipate an effect of Cobenfy KarXT on seizure activity, we note that all patients are located in the EMU environment with 2:1 nursing ratios and immediately available protocols for interventions if seizures occur.
Overview of Memory Testing: Episodic memory tasks in our lab typically last 30-75 minutes provided patient does not request a break during the task. There is no physical risk to participants from cognitive tasks. Participants may stop and resume each task whenever they need a break. Participants for this protocol would need to wait at least 24 hours/six half-lives following completion of one of the testing sessions prior to completing the second, regardless of whether administration of Cobenfy KarXT occurred. The cognitive tasks will cause patients to incur no additional medical or surgical risk; rather patients often report the game-like testing protocols provide relief from the boredom of awaiting seizures. Within each session, patients may request breaks to avoid fatigue. Testing may also be paused or interrupted for any health-care-related needs. The research team will attend to the comfort of all participants, who may discontinue the testing at any time, without repercussions.
Episodic Memory Tasks: Patients will participate in verbal memory tasks, such as lists of specific words to be recalled freely or in a serial order. such lists are comprised of words or nameable pictures. A computer controls stimulus presentation and records participants' response of words or word order. Each list is followed by a brief distractor task consisting of a simple addition or subtraction problem prior to recall. This end-of-list distracter task serves to reduce the large advantage accorded to end-of-list items during recall, or recency effect. There are approximately 10-12 words or items in one list. Participants are then given the opportunity to place these words in the order they recall them. Their responses are digitally recorded by the computer and anonymously stored for later analysis. This paradigm cannot specifically address questions regarding differences on encoding versus retrieval, so patients may be also be given other types of verbal memory tasks, such as recognition paradigms of associative recognition, or other verbal tasks that will be able to parse out such aspects of episodic memory.
Collection of iEEG data: Patients included in the study undergo the acquisition of EEG data for clinical purposes by clinicians, using a computerized EEG collection system. In this study, we will copy these data, strip them of any confidential information, and analyze the raw traces of EEG. Synchronization of the experimental computer with the iEEG signals is accomplished by sending an optically isolated pulse to an input on the EEG recording system. This train of pulses enables the iEEG record to synchronize itself with the testing computer, in standard fashion for this work.
- Conditions
- Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
- Being tested
- COBENFY KarXT (50/20 mg), Control
- Keywords
- oscillatory changest, cholinergic agonist, muscarinic agonist
- Medical subject headings
- Epilepsy, Seizures, Cognitive Dysfunction, Memory Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COBENFY KarXT (50/20 mg)Drug
Patient receives a dose of COBENFY KarXT (50/20 mg) 2 hours prior to episodic memory task.
ControlDrug
Patient receives a dose of placebo 2 hours prior to episodic memory task.
| Study group | Role | What they receive |
|---|---|---|
| COBENFY KarXT (50/20 mg) | Experimental | Subjects will receive a dose of COBENFY KarXT (50/20 mg). Approximately 2 hours minutes after administration, the participant will then complete an episodic memory task session. If the patient completed the control session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session. Receives: Drug: COBENFY KarXT (50/20 mg) |
| Control | Other | Subjects will complete a control session comparator. The participant will then complete an episodic memory task session without receiving the pharmacological intervention. If the patient completed the COBENFY KarXT session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session. Receives: Drug: Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily thetapower and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Measured: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Nov 2025
- Study startDec 2026 (estimated)
- Primary completionDec 2031 (estimated)
- Study completionDec 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by University of Texas Southwestern Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Patients are randomized to COBENFY or a control session by the pharmacy. The study is unblind. Patients complete one session each of the control and COBENFY, in order to evaluate within subject effects on episodic memory processes.
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bradley Lega, University of Texas Southwestern Medical Center
- Investigators
- Bradley C Lega, MD, Principal investigator, University of Texas Southwestern Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07228338
- Sponsor's protocol ID
- STU20250602
- Status last verified
- Sep 2026
- First submitted
- 12 Nov 2025
- Last updated
- 29 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity
- ClinicalTrials.gov ID
- NCT07228338
- Acronym / sponsor ID
- STU20250602
- Conditions
- Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory Loss
- Keywords
- oscillatory changest, cholinergic agonist, muscarinic agonist
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of Texas Southwestern Medical CenterUniversity, hospital or other
- Study start
- Dec 2026 (estimated)
- Primary completion
- Dec 2031 (estimated)
- Study completion
- Dec 2031 (estimated)
- First posted
- 14 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.
The main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.
Participants will complete two treatment arms. One of these will be with the drug, and the other will be control session. Participants will not be blinded to the study condition. Patients will complete a verbal serial recall and/or associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.
Researchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.
Detailed description
Patient Identification: The study team plans to recruit adult patients who are undergoing invasive electroencephalographic (EEG) monitoring as part of standard clinical procedure for the treatment of pharmacologically resistant epilepsy at UT Southwestern. Patients are identified from the pool of patients presented at the epilepsy management conference and approached when they present to the clinic for evaluation for seizure surgery. Patients are screened by a coordinator as well as anesthesiologist on the study team for contraindications which make them ineligible for receiving the drug.
Study procedures: Participation takes place only during the time that the electrodes are surgically in place. Active participation will end when the electrodes are removed. Tasks described below will be administered by key personnel on the study. The data will be de-identified and converted to signal data for processing and analysis. Study personnel, excluding the PI (aka 'experimenters') will perform analysis.
Once patients are in the epilepsy monitoring unit (EMU), subjects will be randomized to receive either a dose of 50 mg/20 mg orally BID of xanomeline and trospium chloride (COBENFY) for their initial session, or complete a control session. Approximately 2 hours after administration in the drug condition, the participant will complete an episodic memory task session. At least 24 hours following the first session (at least four half-lives after the first session), the participant will either receive the agent, or complete the control, depending on the first session. For example, if the patient received COBENFY the first day, they would complete the control the second day, and vice versa. Again, in the drug condition, the episodic memory task would occur 2 hours after administration.
Day 1: Randomized to receive either COBENFY or complete a control session (no drug); Complete episodic memory task session Day 2: Alternative session (control or CONBENFY) from day 1; Completes episodic memory task session
Neither participants nor researchers are blind to administration of Cobenfy KarXT, but this should not greatly impact the science of the study. Although there may be some performance effects, participants are being told that the drug may effect a particular brain activity, which may be difficult to model. The randomization will be generated by the pharmacy using a psuedorandomizer.
The participant's attending nurse will administer Cobenfy KarXT for the drug sessions 2 hours prior to the test.
Physiologic Monitoring: Patients in the epilepsy monitoring undergo EKG and pulse oxygen monitoring in addition to seizure monitoring electrodes at all times as part of routine care and this will not be interrupted during the study period. There is a certified epilepsy monitoring team available should the cholinergic effects enhance seizures. A board-certified anesthesiologist with specialist practice in neuroanesthesia will be immediately available within the hospital to respond with any other concerns. In our previous experiments using cholinergic modulation (antagonism), there have not been any adverse events. Specifically, there has not been an impact on seizure activity. While we do not anticipate an effect of Cobenfy KarXT on seizure activity, we note that all patients are located in the EMU environment with 2:1 nursing ratios and immediately available protocols for interventions if seizures occur.
Overview of Memory Testing: Episodic memory tasks in our lab typically last 30-75 minutes provided patient does not request a break during the task. There is no physical risk to participants from cognitive tasks. Participants may stop and resume each task whenever they need a break. Participants for this protocol would need to wait at least 24 hours/six half-lives following completion of one of the testing sessions prior to completing the second, regardless of whether administration of Cobenfy KarXT occurred. The cognitive tasks will cause patients to incur no additional medical or surgical risk; rather patients often report the game-like testing protocols provide relief from the boredom of awaiting seizures. Within each session, patients may request breaks to avoid fatigue. Testing may also be paused or interrupted for any health-care-related needs. The research team will attend to the comfort of all participants, who may discontinue the testing at any time, without repercussions.
Episodic Memory Tasks: Patients will participate in verbal memory tasks, such as lists of specific words to be recalled freely or in a serial order. such lists are comprised of words or nameable pictures. A computer controls stimulus presentation and records participants' response of words or word order. Each list is followed by a brief distractor task consisting of a simple addition or subtraction problem prior to recall. This end-of-list distracter task serves to reduce the large advantage accorded to end-of-list items during recall, or recency effect. There are approximately 10-12 words or items in one list. Participants are then given the opportunity to place these words in the order they recall them. Their responses are digitally recorded by the computer and anonymously stored for later analysis. This paradigm cannot specifically address questions regarding differences on encoding versus retrieval, so patients may be also be given other types of verbal memory tasks, such as recognition paradigms of associative recognition, or other verbal tasks that will be able to parse out such aspects of episodic memory.
Collection of iEEG data: Patients included in the study undergo the acquisition of EEG data for clinical purposes by clinicians, using a computerized EEG collection system. In this study, we will copy these data, strip them of any confidential information, and analyze the raw traces of EEG. Synchronization of the experimental computer with the iEEG signals is accomplished by sending an optically isolated pulse to an input on the EEG recording system. This train of pulses enables the iEEG record to synchronize itself with the testing computer, in standard fashion for this work.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Patients are randomized to COBENFY or a control session by the pharmacy. The study is unblind. Patients complete one session each of the control and COBENFY, in order to evaluate within subject effects on episodic memory processes.
| Arm | Type | Receives |
|---|---|---|
| COBENFY KarXT (50/20 mg) | Experimental | Drug: COBENFY KarXT (50/20 mg)Subjects will receive a dose of COBENFY KarXT (50/20 mg). Approximately 2 hours minutes after administration, the participant will then complete an episodic memory task session. If the patient completed the control session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session. |
| Control | Other | Drug: ControlSubjects will complete a control session comparator. The participant will then complete an episodic memory task session without receiving the pharmacological intervention. If the patient completed the COBENFY KarXT session already, this session will take place minimum of 24 hours following the initial session, or at least four half-lives after the first session. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 18 - 75 years, all races/ethnicities, and both genders are eligible.
- Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.
- Able to read, understand, and provide written, dated informed consent prior to screening.
- In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.
Key exclusion criteria (13 listed)
- Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.
- Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.
- Hepatic impairment (moderate or severe).
- Renal impairment (moderate or severe).
- Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COBENFY KarXT (50/20 mg)Patient receives a dose of COBENFY KarXT (50/20 mg) 2 hours prior to episodic memory task. | Drug | COBENFY KarXT (50/20 mg) |
| ControlPatient receives a dose of placebo 2 hours prior to episodic memory task. | Drug | Control |
Primary outcome
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the Free recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily thetapower and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the serial recall memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Memory-related changes in brain electrical activity in participants from baseline at Day 2 post-intervention (approx. within 1-3 hrs)
Time frame: Baseline, at Day 2 post-intervention (approx. within 1-3 hrs)
Memory-related changes in brain electrical activity in participants from baseline at post-intervention (approx. within 1-3 hrs) is measured by comparing the associative recognition memory tasks with the electrical readings collected across all bandwidths, but focusing on primarily theta power and oscillatory changes. Other changes, such as phase amplitude coupling, may also be considered.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Epilepsy
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
RecruitingObservational study
Tumor Related Epilepsy
Epilepsy, Cancer
Active, not recruitingPhase 2
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Focal Epilepsy
Enrolling by invitation
Neural Mechanisms for Stopping Ongoing Speech Production (Study 2)
Epilepsy, Speech
Recruiting
Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Refractory Epilepsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Bradley C Lega, MD principal investigator
University of Texas Southwestern Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing COBENFY KarXT (50/20 mg) in people with Epilepsy and Seizures, run by University of Texas Southwestern Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Bradley C Lega, MD (214-648-7816, Bradley.Lega@UTSouthwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Memory-related changes in brain electrical activity in participants from baseline at Day 1 post-intervention (approx. within 1-3 hrs) (time frame: Baseline, at Day 1 post-intervention (approx. within 1-3 hrs)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2026; AzTrials last refreshed its copy on 6 Nov 2026.